YOLFTbeta
Replimune Group Inc

Replimune Group Inc

REPL · NASDAQ · Healthcare / Biotechnology

21.89USD-0.09 (-0.41%)

Price History

Full chart

Market Stats

Previous Close21.98
Open21.78
Day Range20.78 – 22.17
52-Week Range1.50 – 16.33
Volume2.02M
Market Cap1.18B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.15
Dividend Yield0.00%
Beta0.94
50-Day Avg12.95
200-Day Avg8.85

About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sushil Patel Ph.D.
  • Employees465
  • Headquarters500 Unicorn Park Drive, Woburn, MA, United States, 01801, USA
  • Websitehttps://www.replimune.com

Leadership

  • Dr. Sushil Patel Ph.D.CEO & Director · b. 1971
  • Ms. Emily Luisa HillChief Financial Officer · b. 1980
  • Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical Officer · b. 1966
  • Mr. Philip Astley-Sparke F.S.A.Executive Chairman · b. 1971
  • Mr. Andrew SchwendenmanChief Accounting Officer & Treasurer · b. 1976
  • Mr. Shawn Glidden J.D.Senior VP & General Counsel
  • Mr. Camilo Garcia M.A., M.B.A.Chief Human Resource Officer
  • Mr. Paul BullockChief Manufacturing Officer & Framingham Site Head
  • Ms. Nina AragamSenior Vice President of Portfolio Strategy & Program Management
  • Ms. Carolyn TrottSenior Vice President of Quality Assurance

Financials

Income Statement

Currency: USD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue0000000000
Cost of Revenue122.00K109.00K148.00K1.81M4.14M4.58M2.45M2.65M3.50M-
Gross Profit-122.00K-109.00K-148.00K-1.81M-4.14M-4.58M-2.45M-2.65M-3.50M-
Operating Expense9.53M19.12M30.80M54.39M78.62M116.91M174.63M232.12M258.13M-
Operating Income-9.65M-19.23M-30.95M-56.20M-82.76M-121.48M-177.08M-234.77M-261.63M-319.92M
EBITDA-8.08M-16.85M-30.69M-52.58M-76.48M-114.41M-171.72M-227.77M-253.92M-302.30M
Net Income-7.70M-19.70M-30.83M-52.63M-80.87M-118.04M-174.28M-215.79M-247.30M-313.94M
R&D6.94M13.52M22.17M38.76M57.49M80.64M126.53M174.96M189.45M221.18M
Interest Expense0001.92M3.06M2.22M4.16M6.66M7.89M8.86M

Balance Sheet

Currency: USD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets22.82M65.15M154.33M234.10M543.10M461.19M646.59M487.72M551.33M332.39M
Total Liabilities34.33M93.22M16.47M50.38M44.37M49.96M91.30M113.21M135.49M166.23M
Total Equity-11.52M-28.07M137.86M183.72M498.73M411.23M555.29M374.51M415.84M166.16M
Cash20.59M17.58M25.70M59.50M182.52M105.95M146.59M74.46M111.12M209.02M
Total Debt--6.56M41.79M33.28M32.84M60.76M75.87M76.17M111.59M
Net Debt-20.59M-17.58M-19.14M-17.71M-149.24M-73.11M-85.83M1.41M-34.95M-97.44M

Cash Flow

Currency: USD2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-7.08M-16.01M-25.38M-60.55M-61.39M-82.18M-128.05M-185.47M-192.25M-280.34M
Investing Cash Flow-238.00K-44.05M-65.94M-5.23M-188.78M-1.81M-142.50M97.20M-23.80M310.84M
Financing Cash Flow15.00M54.75M101.39M100.17M372.46M6.60M311.30M16.28M252.40M66.29M
Capital Expenditure238.00K136.00K2.60M6.54M2.39M2.34M2.27M5.66M6.69M4.22M
Free Cash Flow-7.32M-16.15M-27.98M-67.09M-63.78M-84.52M-130.32M-191.13M-198.94M-284.57M
Dividends Paid---28.14M91.65M-----
FCF to OCF103.36%100.85%110.25%110.80%103.90%102.84%101.77%103.05%103.48%101.51%
Dividend Paid to FCF----41.95%-143.69%-----

Earnings

Report DateApr 11, 2018Aug 30, 2018Nov 14, 2018Feb 14, 2019Jun 28, 2019Aug 14, 2019Nov 11, 2019Feb 13, 2020Jun 3, 2020Aug 7, 2020Nov 5, 2020Feb 4, 2021May 20, 2021Aug 6, 2021Nov 4, 2021Feb 3, 2022May 19, 2022Aug 4, 2022Nov 3, 2022Feb 9, 2023May 18, 2023Aug 3, 2023Nov 7, 2023Feb 8, 2024May 16, 2024Aug 8, 2024Nov 12, 2024Feb 12, 2025May 22, 2025Aug 7, 2025Nov 6, 2025Feb 3, 2026Jun 29, 2026Aug 14, 2026Nov 5, 2026
EPS Estimate0.00-0.23-0.19-0.25-0.40-0.31-0.34-0.36-0.45-0.43-0.44-0.41-0.38-0.42-0.52-0.57-0.60-0.56-0.76-0.74-0.66-0.84-0.89-0.93-0.80-0.83-0.74-0.72-0.69-0.83-0.79-0.82-0.73-0.72-0.70
EPS Actual-0.42-2.02-0.26-0.24-0.15-0.30-0.35-0.46-0.41-0.44-0.46-0.42-0.41-0.53-0.56-0.57-0.60-0.78-0.79-0.69-0.74-0.75-0.90-0.77-0.25-0.78-0.68-0.79-0.82-0.95-0.90-0.77-0.76-0.72-
Surprise--778.26%-36.84%4.00%62.50%3.23%-2.94%-27.78%8.89%-2.33%-4.55%-2.44%-7.89%-26.19%-7.69%0.00%0.00%-39.29%-3.95%6.76%-12.12%10.71%-1.12%17.20%68.75%6.02%8.11%-9.72%-18.84%-14.46%-13.92%6.10%-4.11%0.00%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap1.18B
Enterprise Value1.14B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book11.56
EPS-3.15
Book Value1.26
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-290.44M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-134.29%
Return on Assets-51.30%
Shares Outstanding94.22M
Shares Float67.65M
Beta0.94
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 8 analystsTarget 19.50
  • Strong Buy
    3
  • Buy
    5

Ownership Breakdown

Institutions
104.25%
Insiders
1.65%
Retail / Other
0.00%

Top Institutional Holders

  • Baker Bros Advisors LP
    11.05M11.72%
  • T. Rowe Price Associates, Inc.
    8.12M8.62%
  • RTW INVESTMENTS, LLC
    7.36M7.81%
  • BlackRock Inc
    6.24M6.62%
  • Suvretta Capital Management, LLC
    4.22M4.48%
  • State Street Corp
    3.78M4.01%
  • FCPM III SERVICES BV
    2.81M2.98%
  • Vanguard Capital Management, LLC
    2.76M2.93%
  • Logos Global Management LP
    2.50M2.65%
  • The Goldman Sachs Group Inc
    2.28M2.42%
  • Erste Asset Management GmbH
    2.12M2.25%
  • FMR Inc
    2.05M2.17%
  • Geode Capital Management, LLC
    1.80M1.91%
  • D. E. Shaw & Co LP
    1.79M1.90%
  • The Toronto-Dominion Bank
    1.59M1.69%
  • ADAR1 Capital Management LLC
    1.58M1.68%
  • Opaleye Management Inc
    1.38M1.47%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    2.90M3.08%
  • iShares Russell 2000 ETF
    2.04M2.17%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.97M2.09%